1. [Bronchiolitis obliterans postallogeneic stem cell transplantation: what is new?].
- Author
-
Lemonnier F, Dhedin N, Catherinot E, Tcherakian C, Neveu H, Suarez F, Becquemin MH, Devillier P, Vernant JP, Couderc LJ, and Rivaud E
- Subjects
- Bronchiolitis Obliterans physiopathology, Bronchiolitis Obliterans therapy, Hematopoietic Stem Cell Transplantation adverse effects, Humans, Risk Factors, Bronchiolitis Obliterans etiology
- Abstract
Bronchiolitis obliterans (BO) is a severe complication of hematopoietic stem cell transplantation (HSCT). It is considered as a respiratory manifestation of chronic graft-versus-host disease. It is quite similar to the bronchiolitis obliterans after lung transplantation. Classical therapy associates steroids and immunosuppressive drugs, however theses procedure showed a modest efficacy and have an important morbidity. Recent progresses in the physiopathology of BO post-HSCT allow to use new treatments: mTOR inhibitors, immunotherapy, extra-corporeal photochemotherapy, and bronchial anti-inflammatory effects of azithromycin, statins or antileucotriens. This review will focus on the use of these new therapies in BO post-HSCT., (2011 Elsevier Masson SAS. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF